Cargando…

Methodological challenges in biomedical HIV prevention trials /

"This IOM committee was formed at the request of the Bill & Melinda Gates Foundation and charged with addressing methodological challenges in late-stage nonvaccine biomedical HIV prevention trials with a specific focus on microbicide and pre-exposure prophylaxis trials."

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: Institute of Medicine (U.S.). Committee on the Methodological Challenges in HIV Prevention Trials
Otros Autores: Gable, Alicia, Lagakos, Stephen W.
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Washington, D.C. : National Academies Press, ©2008.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 a 4500
001 EBOOKCENTRAL_ocn568043994
003 OCoLC
005 20240329122006.0
006 m o d
007 cr cn|||||||||
008 080716s2008 dcua ob 000 0 eng d
040 |a CCO  |b eng  |e pn  |c CCO  |d E7B  |d OCLCQ  |d MMU  |d COD  |d MEAUC  |d IDEBK  |d OCLCQ  |d ORU  |d OCLCQ  |d OCLCF  |d OCLCQ  |d NLGGC  |d YDXCP  |d OCLCQ  |d N$T  |d OCLCQ  |d EBLCP  |d DEBSZ  |d AZK  |d YDX  |d PIFAG  |d ZCU  |d CASUM  |d OCLCQ  |d MERUC  |d OCLCO  |d MERER  |d OCLCQ  |d U3W  |d BUF  |d OCLCO  |d CUY  |d OCLCQ  |d STF  |d WRM  |d COCUF  |d UAB  |d NRAMU  |d EZ9  |d ICG  |d OCLCO  |d VT2  |d AU@  |d OCLCO  |d OCLCQ  |d WYU  |d OCLCA  |d LVT  |d OCLCA  |d DKC  |d OCLCO  |d OCLCQ  |d UKAHL  |d OCLCQ  |d OCLCA  |d UKCRE  |d SDF  |d OCLCO  |d OCLCQ  |d OCLCO  |d OCLCQ  |d OCLCL 
019 |a 228159185  |a 503447125  |a 646755981  |a 666938404  |a 815688524  |a 923278309  |a 961539501  |a 962592791  |a 991959483  |a 999655337  |a 1037925733  |a 1038694359  |a 1045484306  |a 1047537829  |a 1055338406  |a 1064724992  |a 1081248420  |a 1153480511  |a 1156333915  |a 1228565180  |a 1249253468 
020 |a 9780309114318  |q (electronic bk.) 
020 |a 0309114314  |q (electronic bk.) 
020 |z 1281767476 
020 |z 9781281767479 
020 |z 0309114306 
020 |z 9780309114301 
029 1 |a AU@  |b 000051504025 
029 1 |a AU@  |b 000068366150 
029 1 |a DEBBG  |b BV044108822 
029 1 |a DEBSZ  |b 452575621 
029 1 |a NZ1  |b 13335977 
035 |a (OCoLC)568043994  |z (OCoLC)228159185  |z (OCoLC)503447125  |z (OCoLC)646755981  |z (OCoLC)666938404  |z (OCoLC)815688524  |z (OCoLC)923278309  |z (OCoLC)961539501  |z (OCoLC)962592791  |z (OCoLC)991959483  |z (OCoLC)999655337  |z (OCoLC)1037925733  |z (OCoLC)1038694359  |z (OCoLC)1045484306  |z (OCoLC)1047537829  |z (OCoLC)1055338406  |z (OCoLC)1064724992  |z (OCoLC)1081248420  |z (OCoLC)1153480511  |z (OCoLC)1156333915  |z (OCoLC)1228565180  |z (OCoLC)1249253468 
050 4 |a RA643.83  |b .M48 2008eb 
060 4 |a 2008 I-120 
060 4 |a WC 503.6  |b M592 2008 
072 7 |a MBN  |2 bicssc 
072 7 |a POL  |x 027000  |2 bisacsh 
072 7 |a POL  |x 019000  |2 bisacsh 
082 0 4 |a 362.196/9792  |2 22 
049 |a UAMI 
245 0 0 |a Methodological challenges in biomedical HIV prevention trials /  |c Committee on the Methodological Challenges in HIV Prevention Trials, Board on Global Health, Institute of Medicine of the National Academies ; Stephen W. Lagakos and Alicia R. Gable, editors. 
260 |a Washington, D.C. :  |b National Academies Press,  |c ©2008. 
300 |a 1 online resource (xi, 258 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
504 |a Includes bibliographical references. 
520 |a "This IOM committee was formed at the request of the Bill & Melinda Gates Foundation and charged with addressing methodological challenges in late-stage nonvaccine biomedical HIV prevention trials with a specific focus on microbicide and pre-exposure prophylaxis trials." 
588 0 |a Print version record. 
505 0 |a Front Matter -- Reviewers -- Contents -- Summary -- Introduction -- 1 The Status and Challenges of Biomedical HIV Prevention Trials -- 2 Basic Design Features: Size, Duration, and Type of Trials, and Choice of Control Group -- 3 Design Considerations: Risk-Reduction Counseling -- 4 Design Considerations: Pregnancy -- 5 Design Considerations: Adherence -- 6 Design Considerations: Recruitment and Retention -- 7 Site Preparedness -- 8 Estimating HIV Incidence -- 9 Interim Monitoring and Analysis of Results -- 10 Alternative Designs -- Appendixes 
505 8 |a Appendix A: Public Committee Meeting AgendasAppendix B: Acronyms -- Appendix C: Supporting Materials for Chapter 2 -- Appendix D: Methods for Analyzing Adherence -- Appendix E: Committee Biographies 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
650 0 |a AIDS (Disease)  |x Prevention. 
650 1 2 |a HIV Infections  |x prevention & control 
650 1 2 |a Clinical Trials as Topic 
650 2 2 |a Program Evaluation  |x methods 
650 2 2 |a Anti-Infective Agents  |x therapeutic use 
650 2 2 |a Anti-Retroviral Agents  |x therapeutic use 
650 6 |a Sida  |x Prévention. 
650 7 |a POLITICAL SCIENCE  |x Public Policy  |x Social Security.  |2 bisacsh 
650 7 |a POLITICAL SCIENCE  |x Public Policy  |x Social Services & Welfare.  |2 bisacsh 
650 7 |a AIDS (Disease)  |x Prevention  |2 fast 
700 1 |a Gable, Alicia. 
700 1 |a Lagakos, Stephen W. 
710 2 |a Institute of Medicine (U.S.).  |b Committee on the Methodological Challenges in HIV Prevention Trials. 
758 |i has work:  |a Methodological challenges in biomedical HIV prevention trials (Text)  |1 https://id.oclc.org/worldcat/entity/E39PCFVtMyqqMCwjJr9VFmqQpX  |4 https://id.oclc.org/worldcat/ontology/hasWork 
776 0 8 |i Print version:  |t Methodological challenges in biomedical HIV prevention trials.  |d Washington, D.C. : National Academies Press, ©2008  |z 9780309114301  |w (DLC) 2008299718  |w (OCoLC)223867780 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=3378378  |z Texto completo 
938 |a Askews and Holts Library Services  |b ASKH  |n AH36616625 
938 |a Askews and Holts Library Services  |b ASKH  |n AH36558066 
938 |a EBL - Ebook Library  |b EBLB  |n EBL3378378 
938 |a EBSCOhost  |b EBSC  |n 233557 
938 |a YBP Library Services  |b YANK  |n 6011478 
994 |a 92  |b IZTAP